| RIGL |
Rigel Pharmaceuticals, Inc. |
72%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| RIGL |
Rigel Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RIGL graph: Reciprocal relationship from HCM graph: ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismisse… |
| ACCORDINGLY-HUTCHISON-HEALTHCARE-HOLDINGS-LIMITE |
ACCORDINGLY-HUTCHISON-HEALTHCARE-HOLDINGS-LIMITE |
62%
|
o which we become a party might result in substantial costs and divert management’s attention and resources. Furthermore, any litigation, legal disputes, claims or administrative proceedings which ar… |
| ASTRAZENECA-RIGEL-PHARMACEUTICALS-INC |
ASTRAZENECA-RIGEL-PHARMACEUTICALS-INC |
62%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| AZN |
AstraZeneca PLC |
62%
|
Reciprocal relationship from AZN graph: Reciprocal relationship from HCM graph: Reciprocal relationship from AZN graph: Reciprocal relationship from HCM graph: Reciprocal relationship from AZN graph:… |
| CHONGQING-PHARMACEUTICAL-GROUP-CO-LTD |
CHONGQING-PHARMACEUTICAL-GROUP-CO-LTD |
62%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| GP-HEALTH-SERVICE-CAPITAL-CO-LTD |
GP-HEALTH-SERVICE-CAPITAL-CO-LTD |
62%
|
r three manufacturing sites in Suzhou, Shanghai and Switzerland. The Shanghai facility has completed production of our first ATTC candidates. We have also completed production of the first batch of i… |
| HUMAN-GENETIC-RESOURCES |
HUMAN-GENETIC-RESOURCES |
62%
|
e or system breakdown. We also cooperate with third parties including collaboration partners, principal investigators, hospitals, CROs and other third-party contractor and consultants for our clinica… |
| HUMAN-RESOURCES |
HUMAN-RESOURCES |
62%
|
to do so, with an overall objective to expand basic medical insurance coverage and improve the quality and reliability of healthcare services. Specific upcoming regulatory and policy changes remain u… |
| HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED |
HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED |
62%
|
ee months’ prior written notice. The executive officer may also voluntarily terminate his/her employment with us upon not less than three months’ prior written notice to us. 217 Table of Contents E… |
| HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED-HUTCHISON- |
HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED-HUTCHISON- |
62%
|
o which we become a party might result in substantial costs and divert management’s attention and resources. Furthermore, any litigation, legal disputes, claims or administrative proceedings which ar… |
| HUTCHISON-WHAMPOA-ENTERPRISES-LIMITED |
HUTCHISON-WHAMPOA-ENTERPRISES-LIMITED |
62%
|
tated on June 15, 2021) with Hutchison Whampoa Enterprises Limited, an indirect wholly-owned subsidiary of CK Hutchison, pursuant to which we have been granted a non-exclusive, non-transferrable, roy… |
| HUTCHMED-HOLDINGS-LIMITED |
HUTCHMED-HOLDINGS-LIMITED |
62%
|
warehousing, the producers and the sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put int… |
| HUTCHMED-LIMITED |
HUTCHMED-LIMITED |
62%
|
ee months’ prior written notice. The executive officer may also voluntarily terminate his/her employment with us upon not less than three months’ prior written notice to us. 217 Table of Contents E… |
| IKENA-ONCOLOGY-INC |
IKENA-ONCOLOGY-INC |
62%
|
estment of an aggregate 45% equity interest out of 50% in Shanghai Hutchison Pharmaceuticals to third parties for cash consideration of approximately $608.5 million. On July 25, 2025, Inmagene announ… |
| JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD |
JIANGSU-HENGRUI-PHARMACEUTICALS-CO-LTD |
62%
|
da In January 2023 (as amended in June 2025), we entered into a license agreement with a subsidiary of Takeda (the “ Takeda Agreement ” ) to further the global development, commercialization and manu… |
| LIMITED-JOINTOWN-PHARMACEUTICAL-GROUP-CO-LTD |
LIMITED-JOINTOWN-PHARMACEUTICAL-GROUP-CO-LTD |
62%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| LUYE-PHARMA-HONG-KONG-LTD |
LUYE-PHARMA-HONG-KONG-LTD |
62%
|
omers: PRC 407,454 452,413 484,895 US and Others 141,058 177,788 353,104 548,512 630,201 837,999 December 31, 2025 2024 US and … |
| SHANGHAI-JUNSHI-BIOSCIENCES-CO-LTD |
SHANGHAI-JUNSHI-BIOSCIENCES-CO-LTD |
62%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD-CHINA-RE |
SHANGHAI-PHARMACEUTICALS-HOLDING-CO-LTD-CHINA-RE |
62%
|
ber 14, 2021 to set aside the final award which was heard by the High Court in Hong Kong on June 28, 2022 and dismissed by the judge on July 26, 2022. Luye obtained leave to appeal the setting aside … |
| SUZHOU-LIMITED |
SUZHOU-LIMITED |
62%
|
ur five largest customers as of the date of the filing of this annual report. In 2023, 2024 and 2025, Sinopharm, which jointly owns the Distribution Business with us, was one of our five largest cust… |
| THEREFORE-HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED |
THEREFORE-HUTCHISON-HEALTHCARE-HOLDINGS-LIMITED |
62%
|
o which we become a party might result in substantial costs and divert management’s attention and resources. Furthermore, any litigation, legal disputes, claims or administrative proceedings which ar… |
